James Chung-Man Ho
Overview
Explore the profile of James Chung-Man Ho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
932
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan M, Lam S, Yan S, Feng Y, Chen C, Ko F, et al.
J Cancer Res Ther
. 2024 Aug;
20(4):1224-1231.
PMID: 39206985
Purpose: Malignant and aggressive, small cell lung cancer (SCLC) constitutes about 15% of all diagnosed lung cancer cases. With primary therapeutic options such as chemotherapy accompanied by debilitating side effects,...
2.
Chan K, Ma T, Sridhar S, Lui M, Ho J, Lam D, et al.
J Infect Public Health
. 2024 Jul;
17(9):102511.
PMID: 39068731
Background: COVID-19 pandemic has disrupted tuberculosis (TB) services in many countries, but the impacts on sites of involvement, drug susceptibility, smear positivity and clinical outcomes, and clinical outcomes of co-infection...
3.
Kwok W, Lung D, Tam T, Yap D, Ma T, Tsui C, et al.
Vaccines (Basel)
. 2024 Jul;
12(7).
PMID: 39066342
Influenza is an important respiratory viral pathogen in adults, with secondary bacterial pneumonia being a common complication. While pneumococcal vaccines can prevent pneumococcal pneumonia and invasive pneumococcal disease, whether they...
4.
Takemura N, Cheung D, Fong D, Hui D, Lee A, Lam T, et al.
J Pain Symptom Manage
. 2024 May;
68(2):171-179.
PMID: 38729532
Context: Dyspnea, a prevalent and debilitating symptom in patients with advanced lung cancer, negatively affects symptom burden and prognosis. Physical activity has emerged as a promising non-pharmacological intervention for managing...
5.
Takemura N, Cheung D, Fong D, Lee A, Lam T, Ho J, et al.
J Cancer Surviv
. 2024 May;
PMID: 38691272
Purpose: Cancer-related cognitive impairment is prevalent in metastatic lung cancer survivors. This study aimed to compare the effectiveness of aerobic exercise and Tai Chi on perceived cognitive function and the...
6.
Kwok W, Tsui C, Isaac Leung S, Wong C, Tam T, Ho J
BMJ Open Respir Res
. 2024 Apr;
11(1).
PMID: 38637114
Background: Although bronchiectasis is reported to be associated with cardiovascular disease, evidence for an association with cardiovascular events (CVEs) is lacking. Methods: A territory-wide retrospective cohort study was conducted in...
7.
Kwok W, Teo K, Lau K, Ho J
BMC Pulm Med
. 2024 Feb;
24(1):80.
PMID: 38350918
Background: Elevation of systemic inflammatory markers were found to correlate with increased disease extent, reduced lung function and higher risk of future severe exacerbations in patients with bronchiectasis. Although a...
8.
Takemura N, Cheung D, Fong D, Lee A, Lam T, Ho J, et al.
JAMA Oncol
. 2023 Dec;
10(2):176-184.
PMID: 38060250
Importance: Sleep disturbances prevalent among patients with advanced lung cancer can aggravate physical and psychological symptoms, contributing to decreased quality of life and survival. Objective: To compare the effectiveness of...
9.
Soo R, de Marinis F, Han J, Ho J, Martin E, Servidio L, et al.
Clin Lung Cancer
. 2023 Nov;
25(1):80-84.
PMID: 37914594
Introduction: Osimertinib is a central nervous system (CNS)-active, third generation, irreversible, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance...
10.
Chiu J, Lee S, Ho J, Park Y, Chao T, Kim S, et al.
Drug Saf
. 2023 Aug;
46(10):927-949.
PMID: 37552439
Trastuzumab deruxtecan (T-DXd)-an antibody-drug conjugate targeting the human epidermal growth factor receptor 2 (HER2)-improved outcomes of patients with HER2-positive and HER2-low metastatic breast cancer. Guidance on monitoring and managing T-DXd-related...